2022
DOI: 10.3390/jcm11164832
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Background: To evaluate the safety, efficacy, and predictability of laser-assisted in situ keratomileusis (LASIK) enhancement after primary LASIK and compare to Food and Drug Administration (FDA) criteria. Methods: Patients who underwent LASIK enhancement after primary LASIK between 2002 and 2019 were compared to those who underwent LASIK without retreatment. Patient demographics, preoperative characteristics, visual outcomes, and postoperative complications were compared between groups. Epithelial ingrowth (E… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 57 publications
0
2
0
Order By: Relevance
“…The procedure received US FDA approval in 2001 [ 15 , 16 ]. It should be noted that the development of refractive surgery has contributed to the femtosecond laser, being replaced by the microkeratome in flap formation [ 17 ]. FS-LASIK is recommended for patients with high myopia (−6.00 D to −12.00 D).…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…The procedure received US FDA approval in 2001 [ 15 , 16 ]. It should be noted that the development of refractive surgery has contributed to the femtosecond laser, being replaced by the microkeratome in flap formation [ 17 ]. FS-LASIK is recommended for patients with high myopia (−6.00 D to −12.00 D).…”
Section: Introductionmentioning
confidence: 99%
“…FS-LASIK is recommended for patients with high myopia (−6.00 D to −12.00 D). In addition, in comparison with the LASEK procedure, fewer cases of dry eyes were observed [ 17 ].…”
Section: Introductionmentioning
confidence: 99%